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Abstract
Nuclear respiratory factor-1 (NRF-1) stimulates the transcription of nuclear-encoded genes that
regulate mitochondrial genome transcription and biogenesis. We reported that estradiol (E2) and 4-
hydroxytamoxifen (4-OHT) stimulate NRF-1 transcription in an estrogen receptor α- and β- (ERα,
ERβ) dependent manner in human breast cancer cells. The aim of this study was to determine if E2
and 4-OHT increase NRF-1 in vivo. Here we report that E2 and 4-OHT increase NRF-1 expression
in mammary gland and uterus of ovariectomized C57BL/6 mice in a time-dependent manner. E2
increased NRF-1 protein in the uterus and mammary gland; however, in mammary gland, 4-OHT
increased Nrf1 mRNA but not protein. Chromatin immunoprecipitation (ChIP) assays revealed
increased in vivo recruitment of ERα to the Nrf1 promoter and intron 3 in mammary gland and
uterus 6 h after E2 and 4-OHT treatment, commensurate with increased NRF-1 expression. E2 and
4-OHT- induced increases in NRF-1 and its target genes Tfam, Tfb1m, and Tfb2m were
coordinated in mammary gland but not uterus, due to uterine-selective inhibition of the expression
of the NRF-1 coactivators Ppargc1a and Ppargc1b by E2 and 4-OHT. E2 transiently increased
NRF-1 and PGC-1α nuclear staining while reducing PGC-1α in uterus. E2, not 4-OHT, activates
mitochondrial biogenesis in mammary gland and uterus in a time-dependent manner. E2 increased
mitochondrial outer membrane Tom40 protein levels in mammary gland and uterus whereas 4-
OHT increased Tom40 only in uterus. These data support the hypothesis of tissue-selective
regulation of NRF-1 and its downstream targets by E2 and 4-OHT in vivo.
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Introduction
Uterus and mammary gland are classical estrogen target tissues in which estrogens, e.g.,
17β-estradiol (E2), bind estrogen receptors α and β (ERα and ERβ) to regulate gene
expression and physiological functions (Faulds, et al. 2012). Studies in female ERα and ERβ
knockout mice (αERKO and βERKO) demonstrated that ERα is critical for mammary gland
formation and sexual maturation of the reproductive tract whereas ERβ is essential for
*
 author to whom correspondence should be addressed: Carolyn M. Klinge, Department of Biochemistry & Molecular Biology; Center
for Genetics and Molecular Medicine, University of Louisville School of Medicine, Louisville, KY 40292 USA;
carolyn.klinge@louisville.edu Phone: 502-852-3668; Fax: 502-852-3659.
DISCLOSURE STATEMENT: The authors have nothing to disclose
NIH Public Access
Author Manuscript
J Mol Endocrinol. Author manuscript; available in PMC 2014 May 01.
Published in final edited form as:
J Mol Endocrinol. 2013 October ; 51(2): 233–246. doi:10.1530/JME-13-0051.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
ovarian function, but not mammary gland or uterus (Couse and Korach 1999). Although
many tissue-specific phenotypes for αERKO, βERKO, and other ERα knockout mice have
been reported (Billon-Galés, et al. 2009; Korach, et al. 2003; Pendaries, et al. 2002), how
estrogens regulate mitochondrial biogenesis and energy production by oxidative
phosphorylation (OXPHOS) in uterus and mammary gland is largely undefined.
Weight gain by postmenopausal women and ovariectomized rodents and the preservation of
muscle mass and inhibition of adipogenesis by hormone replacement therapy (Cooke and
Naaz 2004) provide clear evidence for the stimulatory effects of endogenous estrogens on
metabolism, but does not address the effects of endogenous estrogens on specific tissues.
Estrogens regulate mitochondrial biogenesis and function in normal and cancer cells through
nuclear, mitochondrial, plasma membrane - initiated events that have been reviewed (Klinge
2008; Simpkins, et al. 2008; Simpkins, et al. 2010; Yager and Chen 2007). The specific
roles for ERα and ERβ in regulating estrogens’ tissue-specific effects on energy, glucose
homeostasis, and insulin sensitivity were recently reviewed (Faulds et al. 2012). In addition
to central brain actions to regulate appetite and satiety (Barros and Gustafsson 2011), ERα
maintains metabolic control in skeletal muscle, white adipose tissue, liver, and pancreas by
stimulating insulin signaling, while activated ERβ results in a diabetogenic/adipogenic
phenotype, although questions remain (Faulds et al. 2012). The mechanisms and gene
targets by which ERα and ERβ regulate metabolic pathways are largely unknown, certainly
tissue-specific (Barros and Gustafsson 2011), and involve complex crosstalk with multiple
signaling pathways including other nuclear receptors (NRs), e.g., peroxisome proliferator-
activated receptors α and γ (PPARα, PPARγ) (Papi, et al. 2013) and estrogen related
receptors (ERRs) (Deblois and Giguere 2013); coregulators, e.g., PPARγ coactivator
(PGC-1) family proteins (Scarpulla, et al. 2012); and plasma membrane receptors (Renoir, et
al. 2013).
We reported that E2 and 4-hydroxytamoxifen (4-OHT), an active tamoxifen (TAM)
metabolite, stimulate transcription of nuclear-encoded nuclear respiratory factor 1 (NRF-1)
by binding ERα and ERβ, respectively, and increasing ERα, ERβ, and RNA polymerase II
recruitment to the promoter of NRF1 in MCF-7 breast cancer cells (Ivanova, et al. 2011;
Mattingly, et al. 2008). NRF-1 regulates the transcription of nuclear-encoded, mitochondrial
genes, e.g., mitochondrial transcription factors TFAM, TFB1M, and TFB2M, and nuclear
encoded components of OXPHOS, e.g., cytochrome c (CYCS) (Cam, et al. 2004; Richard C
2011; Scarpulla 2006; Scarpulla 2008a). In MCF-7 cells, E2-induced NRF-1 resulted in an
increase in expression of Tfam and increased mitochondrial biogenesis (Mattingly et al.
2008). NRF-1's activity depends on its interaction with coactivators PGC-1α, PGC-1β, and
PRC (Gleyzer and Scarpulla 2011; Richard C 2011; Scarpulla 2008a, 2012). Little is known
about how estrogens or antiestrogens regulate the expression or activity of these coactivators
in uterus or mammary gland. One study reported that E2 reduced PGC-1α specifically in the
uteri of immature and adult mice (Macari, et al. 2010a). Concordantly, ovariectomy
increased PGC-1α in mouse brain endothelial cells (Kemper, et al. 2013).
Most studies of the regulation of mitochondrial biogenesis by NRF-1 and the PGC-1 family
have been performed in tissues with high oxidative activity: skeletal muscle, liver, brown
fat, and heart (Finck and Kelly 2006, 2007; Scarpulla 2008b). There are no specific studies
of how estrogens regulate mitochondrial biogenesis in mammary gland and only one study
in mouse uterus (Macari et al. 2010a). Although microarray analysis of gene expression in
mouse uterus identified many genes regulated by E2 and TAM (Fong, et al. 2007; Fong, et
al. 2010; Moggs, et al. 2004), Nrf1 was not included in the microarray platforms. GEO
profile # GDS2208 / 9902 revealed that Nrf1 was increased in C57BL/6 mouse uterus by 6 h
of E2 treatment (Hewitt, et al. 2012). Another study of uterine gene expression revealed
lower Nrf1 in SRC-2−/− compared to wild type adult mice (Jeong, et al. 2007). SRC-2 is a
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well-established coactivator for ERα and upregulated by E2 in adult uteri (Klinge 2000;
O'Malley and Kumar 2009) (Jeong et al. 2007). Microarray profiling of E2-regulated genes
in aortas of wild type, ERα, and ERβ knockout mice revealed opposite regulation of Nrf1
and many NRF-1-regulated mitochondrial respiratory chain (MRC) genes by ERα and ERβ
(O'Lone, et al. 2007). E2-ERα increased whereas E2-ERβ reduced expression of Nrf1 and
MRC genes in mouse aorta (O'Lone et al. 2007). Nrf1 was not included in a microarray
profiling E2-regulated genes in mouse mammary gland (Deroo, et al. 2009). Hence, how E2
and TAM regulate of NRF-1, PGC-1 coactivators, NRF-1 regulated genes, and
mitochondrial biogenesis in uterus and mammary gland in vivo is unknown. Similarly,
regulation of mitochondrial biogenesis, by antiestrogens, e.g., TAM, in uterus where TAM
is an agonist (Sourla, et al. 1997) is largely undefined (Klinge 2008).
Ovariectomy was recently shown to decrease the expression of NRF-1, TFAM, and PGC-1β
while increasing PGC-1α in isolated brain endothelial cells from C57BL/6 mice (Kemper et
al. 2013). Ovariectomy reduced the mitochondrial biogenesis ~ 20% and decreased the
expression of manganese superoxide dismutase (MnSOD) and ATP synthase subunit α,
Complex 5 suggesting that ovarian hormones normally stimulate mitochondrial biogenesis
but suppress ROS in brain endothelium by inducing anti-oxidant proteins (Kemper et al.
2013). This agrees with many reports on the protective effect of estrogens against brain
injury (Simpkins et al. 2010).
The goal of this study was to test the hypothesis that E2 and 4-OHT stimulate NRF-1 gene
expression and coordinately activate downstream nuclear and mitochondrial gene expression
and mitochondrial biogenesis in vivo in a tissue-selective manner. To address this
hypothesis, ovariectomized (ovex) mice were administered a single dose of E2 (100 ng/
mouse) or 4-OHT (50 μg/mouse). NRF-1 and its target genes, both nuclear and
mitochondrial (mt), mt biogenesis, and mt/nuclear DNA ratio were examined 6, 24, and 72 h
post injection based on a previous study (O'Brien, et al. 2006). Our results support our
hypothesis and reveal novel tissue-selective actions of E2 and 4-OHT in regulating NRF-1,
its coregulators, and its downstream gene targets in mouse mammary gland and uterus.
Materials and Methods
Chemicals
17β-estradiol (E2), 4-hydroxytamoxifen (4-OHT), and sesame oil were purchased from
Sigma-Aldrich (St. Louis, MO, USA).
Antibodies
Antibodies were purchased as follows: ERα (HC-20) and Tom40 (H-300), Santa Cruz
Biotechnology (Santa Cruz, CA, USA); NRF-1, Rockland Immunochemicals, Inc.
(Gilbertsville, PA, USA); Tfam (DO1P), Abnova, (Taipei, Taiwan); nuclear-encoded
cytochrome c oxidase subunit IV (COX4-1, nuclear-encoded, MitoSciences, Eugene, OR,
USA); Cytochrome C Ab-2, Thermo Fisher Scientific (Fremont, CA, USA), β-actin, Sigma-
Aldrich.
Animals
C57BL/6 mice, ovariectomized on postnatal day 20, were purchased from Charles River
Laboratories (Wilmington, MA, USA) on postnatal day 25. All animal studies were
conducted in accordance with procedures outlined in the NIH Guide to the Care and Use of
Experimental Animals as approved by the AALAC-accredited University of Louisville
Institutional Animal Care and Use Committee. After 14 d quarantine, mice were randomized
into three groups of five/group. Mice were given a single subcutaneous (sc) injection
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(between the shoulders) of vehicle control (sesame oil, 100 μl), E2 (100 ng/mouse), or 4-
OHT (50 μg/mouse) and tissues were harvested at 6, 24 and 72 h after injection. A total of
15 mice were included in each treatment group and time point within each experiment and
three separate experiments were performed. All mice were injected with vehicle control at
8:30 am, followed by E2 at 9 am, and 4-OHT at 10 am with tissues harvested 6, 24, and 72 h
after injection. There is no variation in Nrf1 transcript expression in mouse prefrontal cortex
during a 24 h (12 h light:12 h dark) cycle (GDS3080), similar to the conditions used in our
experiment. There is no evidence that Nrf1 gene expression varies with circadian rhythm
(Bozek, et al. 2009; Bozek, et al. 2010).
Mice and treatments for IHC studies
Female mice were obtained by mating near congenic C57BL/6 animals (129/C57BL/6 mice
were backcrossed to C57BL/6 for 8 generations; i.e., 99.61% of the genome was contributed
by C57BL/6). Mice were ovariectomized at four to six weeks of age and rested for 2 weeks.
They were then i.p. injected with ethanol vehicle or 1 μg of 17β-estradiol (Sigma-Aldrich)
for 24 or 48 h. All procedures were carried out according to animal protocols approved by
the University of Houston Institutional Animal Care and Use Committee.
Tissue processing and immunohistochemistry
Uteri were harvested, fixed in 4% paraformaldehyde, and embedded in paraffin. Serial
sections were made longitudinally at 5-μm thickness. Sections were deparaffinized,
rehydrated, and microwaved in 10 mM sodium citrate buffer (pH 6.0) for 20 minutes as
previously described (Balsitis, et al. 2003). Non-specific antibody binding was blocked by
incubating sections in 5% donkey serum (Santa Cruz Biotechnology) in PBS for 1hr.
Sections were serially incubated with rabbit anti-NRF-1 antibody (1:200 in 5% donkey
serum, Sigma-Aldrich) and then goat anti-PGC-1α (1:50 in 5% donkey serum, Novus
Biologicals) at 4°C overnight; normal rabbit IgG and normal goat IgG (Santa Cruz
Biotechnology) were used as negative controls. Anti-rabbit IgG-Alexa Fluor 488
(Invitrogen) and anti-goat IgG-CFL 594 (Santa Cruz Biotechnology) were used as secondary
antibodies. Nuclei were stained with Hoechst 33258 (Sigma-Aldrich). Tissues were
visualized with an Olympus FV1000 laser scanning confocal microscope.
RNA Isolation and Quantitative Real-Time-PCR (qPCR)
RNA was extracted using the RNeasy Mini Kit from Qiagen (Valencia, CA, USA). The
High Capacity cDNA archive kit (PE Applied Biosystems, Foster City, CA, USA) was used
to reverse-transcribe RNA using random hexamers. Supplementary Table 1 lists gene and
protein names and abbreviations. Murine mRNA transcript levels of Nrf1, Tfam, CycS, Cox4
were analyzed using SYBR Green dye (RT2SYBR®Green ROX qPCR, QIAGEN). Tfb1m
and Tfb2m expression levels were analyzed by one-step qPCR (Power SYBR® Green RNA-
to-Ct 1-step kit, Applied Biosystems). Relative transcription levels were normalized to 18S
rRNA or 36b4 mRNA (Macari, et al. 2010b). 18S rRNA primers and probe were purchased
as Assays-on-Demand™ Gene Expression Products (PE Applied Biosystems). Murine
Tfb1m and Tfb2m primers were from RealTimePrimers (Elkins Park, PA). The mouse
Ppargc1a, Tfam, cytochrome c, Cox4 primer sequences were reported in (Safdar, et al.
2011) and were purchased from IDT (Coralville, IA, USA). The mouse Nrf1 primers were
also purchased from IDT: forward: 5’-GCACCTTTGGAGAATGTGGT-3’; reverse: 5’-
CTGAGCCTGGGTCATTTTGT-3’.
Transcript expression analysis was determined between the control and E2 or 4-OHT treated
groups and individual samples were run in triplicate. qPCR was performed in the ABI
PRISM 7900 SDS 2.1 or ViiA7 real-time PCR systems (PE Applied Biosystems) using
relative quantification. Analyses and fold differences were determined using the
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comparative CT method. Fold change was calculated from the ΔΔCT values with the
formula 2−ΔΔCT and data are presented as relative to expression in control (sesame oil-
injected) mice.
Protein Isolation
Whole tissue extracts were prepared in radioimmunoprecipitation (RIPA) buffer and
protease inhibitor (Roche) (Mattingly et al. 2008) with a mechanical homogenizer (Omni
International, Kennesaw, GA, USA). Protein concentrations were determined using the Bio-
Rad DC Protein Assay (Bio-Rad, Hercules, CA, USA).
Western Blot
Western blotting followed standard procedures (Ivanova et al. 2011; Mattingly et al. 2008).
In brief, 30-40 μg of protein lysates (see individual Figures) were separated on 10 or 14 %
SDS PAGE gels and electroblotted to PVDF membranes. Data were captured and analyzed
by Carestream Image Station 4000 R Pro with Carestream Molecular Imaging Software,
version 5.0, (Carestream Health, Inc., New Haven, CT, USA). The values from regions of
interest (ROI) normalized to the loading control, e.g., β-actin or Ponceau S staining, and the
normalized value of the control was set to 1 for comparison between separate experiments.
Chromatin Immunoprecipitation (ChIP) Assay
ChIP was performed with the MAGnify™ Chromatin Immunoprecipitation System
(Invitrogen) using the manufacturer's protocol. Half of the uterus or the left inguinal
mammary gland from one mouse was fixed in 1% formaldehyde at room temperature 20
min. Then the reaction was terminated by addition of 0.125 M glycine for 5 min at room
temperature followed by sedimentation and a wash with ice cold PBS. After aspiration of the
PBS, the tissues were frozen at −80°C. The tissues were mechanical homogenized in ChIP
buffer (Ivanova et al. 2011) and genomic DNA was shared by sonication on ice. 300 μg of
lysed extracts were incubated with anti-ERα (HC-20) antibody or normal rabbit IgG (both
from Santa Cruz). DNA was eluted from the beads by incubating with 100 μl of 10% Chelex
(Bio-Rad) at 95°C for 10 min, followed by Proteinase K treatment and heat inactivation at
95°C for 10 min. Following centrifugation, the supernatant was used for PCR amplification.
The primers used for qPCR contained the mouse Nrf1 promoter (−962 bp) region with
estrogen response element (ERE) were sense 5’- GATCTCTGGGTTGGAGGTC-3’ A and
antisense 5’-ATAAATGCCCCACATGGTGT-3’ (see diagram in Fig. 2A); and ‘close to
ERE’ primers were sense: 5’ CTCTTAACCGCTGAGCCATC-3’ and antisense: 5’-
AGGGAAAGGGAGGAGATTCA-3’. The primers containing the Nrf1 intron 3 region with
AP-1 and ½ERE binding sites were sense: 5’-TTTGACTTGATACATGTGAATGC-3’, and
antisense: 5’-TCTCTGTGAAATAACTGACAGAAAT-3’. Real time-PCR was performed
using 2 μl of purified DNA and SYBR Green Master Mix (SuperArray Bioscience Corp.,
Frederick, MD, USA). Relative promoter enrichment was compared with IgG for each
treatment. ChIP using primers to an intron 6 region of Nrf1: 5’-
CAGGCAGAGGTGGAGCTAAC-3’ and 5’-CACTGGGCCCTAGCAAATAC–3’ were
used as a negative control. The Ct values for ChIP with IgG to any of the primers or ChIP
for ERα with primers for intron 6 were “undetectable” > 35 ± 0.5.
Mitochondrial/Nuclear DNA Ratios
The relative mitochondrial content of mammary gland and uterus was determined using
SYBR green qPCR measuring the ratio of mitochondrial- encoded nicotinamide adenine
dinucleotide dehydrogenase-5 (mt-Nd5)/ nuclear-encoded cystic fibrosis (Cftr) (Bauerly, et
al. 2006). For nuclear and mitochondrial DNA quantification, 10 ng and 0.1 ng DNA were
used as template, respectively (Bauerly et al. 2006). Each sample was analyzed in triplicate.
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Relative mitochondrial copy number to nuclear copy number was assessed by a comparative
Ct method, using the following equation: ΔCtmitochondria/nuclear = Ctmitochondria − Ctnuclear.
The fold-change relative to control animals was calculated using the following equation:
2(−ΔΔCt) mitochondria/nuclear, where ΔΔCt mitochondria/nuclear = ΔCtcontrol mitochondria/nuclear
−ΔCtmitochondria/nuclear of each animal from different treatment and time groups (Bauerly et
al. 2006). Values represent mean fold change ± SEM.
Statistical Analysis
Statistical evaluation of the data was performed using Student's t-test in Excel and one-way
ANOVA followed by Student-Newman-Keuls or Dunn's post-hoc tests using GraphPad
Prism.
Results
E2 and 4-OHT increase Nrf1 expression in both mammary gland and uterus
We previously reported that E2 and 4-OHT increase NRF1 transcription in MCF-7 and
T47D breast cancer cells and human umbilical vein endothelial cells (Ivanova et al. 2011;
Mattingly et al. 2008; Mattingly and Klinge 2012), but the effect of E2 and 4-OHT on NRF1
transcription in estrogen target tissues in vivo is unknown. The expression of Nrf1 was
measured in the mammary gland and uterus of ovariectomized C57BL/6 mice after
treatment with vehicle (sesame oil), E2, or 4-OHT for 6, 24, or 72 h (Fig. 1A and 1B). Nrf1
transcript expression was increased by E2 in mammary gland after 6 and 72 h and in the
uterus after 6 and 24 h, but not at 72 h. 4-OHT increased Nrf1 expression in both mammary
gland and uterus 6 h after treatment, but reduced Nrf1 in the mammary gland, but not in the
uterus, after 24 h. Nrf1 expression returned to basal in both mammary gland and uterus 72 h
after 4-OHT treatment. Basal Nrf1 transcript expressed was unchanged during the time
course of treatment (Supplementary Fig. 1)
Tissue-specific regulation of NRF-1 protein expression by E2 and 4-OHT
Commensurate with E2-and 4-OHT-induced Nrf1 mRNA, NRF-1 protein increased in uterus
6 and 24 h after treatment with a return to basal levels after 72 h (Fig. 1D and
Supplementary Fig. 1). E2 increased NRF-1 protein in mammary gland only 72 h after E2
treatment while 4-OHT was without effect (Fig. 1C and Supplementary Fig. 1).
ERα binding to mouse Nrf1 promoter in vivo
Chromatin immunoprecipitation (ChIP) assays were used to investigate ERα binding to the
mouse Nrf1 promoter. The location of the primers for ChIP are shown in Figure 2A. These
regions were chosen based on known or predicted EREs and other elements regulated by ER
tethering mechanisms (Supplementary Fig. 2). E2 increased ERα recruitment to the ERE-
containing region within the 5’ promoter in mammary gland and uterus 6 h after treatment
(Fig. 2B, C). However, E2-ERα was not recruited to the ½ ERE/AP-1 site located in intron 3
in either mammary gland or uterus (Fig. 2B, C). 4-OHT increased ERα recruitment to the
ERE in both tissues and to the ½ ERE/AP-1 region (ChIP primer 1) in the mammary gland.
ERα recruitment corresponds to increased Nrf1 expression detected 6 h after treatment with
E2 in both the mammary gland and uterus (Fig. 1A, B). 4-OHT-ERα was recruited to the ½
ERE /AP-1 binding site in the intron 3 region in the mammary gland, but not uterus.
E2 and 4-OHT increase selected NRF-1 target genes in mammary gland
An increase in NRF-1 protein is expected to increase the transcription of its target genes,
e.g., Tfam, Tfb1m, and Tfb2m, involved in regulation of mtDNA transcription and
replication. Correspondingly, we detected an increase in Tfam and Tfb1m in mammary gland
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6 h after treatment with E2 and 4-OHT (Fig. 3A). The pattern of Tfam, Tfb1m, and Tfb2m
gene expression was different in uterus. E2 and 4-OHT repressed Tfb1m in the uterus 6 h
after treatment and in the 4-OHT-treated mice, Tfb1m remained repressed after 24 h. 4-OHT
reduced uterine Tfam below control levels after 24 h, but expression returned to control
levels by 72 h (Fig. 3B). While unchanged at 24 h, E2 increased Tfam and Tfb1m expression
after 72 h in both mammary gland and uterus (Fig. 3 A, B). No increase in Tfb2m was
detected in response to either E2 or 4-OHT in either mammary gland or uterus (Fig. 3A, B).
E2 and 4-OHT reduced Tfb2m in the uterus 24 h after treatment and 4-OHT reduced Tfbm2
in the mammary gland 72 h after treatment (Fig. 3A, B).
E2 and 4-OHT increase Tfam protein in mammary gland and 4-OHT reduces Tfam protein in
uterus
E2 and 4-OHT increased Tfam protein in mammary gland 72 h after treatment (Fig. 3C and
Supplementary Fig. 3). Reflecting the lack of induction of Tfam mRNA expression by E2 or
4-OHT in uterus (Fig. 3B), no increase in Tfam protein was detected in uterus 6 or 24 h after
treatment or with E2 72 h after treatment (Fig. 3D and Supplementary Fig. 3). Uterine Tfam
protein levels were lower than control 72 h after 4-OHT treatment. Concordantly, expression
of mitochondrial-encoded cytochrome c oxidase I (mt-Co1) was significantly reduced by 4-
OHT-treatment in uterus 24 and 72 h after treatment while no changes were detected in
mammary gland (Supplementary Fig. 4).
E2 activated and 4-OHT inhibited mitochondrial biogenesis
Tfam is crucial for the initiation of mitochondrial transcription and DNA replication
(Campbell, et al. 2012). Since E2 and 4-OHT increased Tfam protein in the mammary gland,
we examined the mitochondrial/nuclear DNA as an index of mitochondrial biogenesis. As
recently reviewed (Kemper et al. 2013), mitochondrial /nuclear DNA ratios are a better
marker of mitochondrial biogenesis than mitochondrial staining techniques. The
mitochondrial/nuclear DNA ratio was determined by qPCR using primers for mt-Nd5 as a
mitochondria gene and Cftr (cystic fibrosis) as a nuclear gene (Bauerly et al. 2006).
Although E2 increased the mitochondrial /nuclear DNA ratio in mammary gland at 6 h, this
was not statistically significant until 24 h (Fig. 4A). 4-OHT decreased mitochondrial
biogenesis in the mammary gland after 72 h. In the uterus, E2 increased mitochondrial
biogenesis 24 and 72 h after E2 treatment whereas 4-OHT had no effect (Fig. 4B). We
conclude that E2 increased mitochondrial biogenesis in both mammary gland and uterus,
with a higher increase in uterus, which may reflect E2-induced increases in transcription,
protein synthesis, and cell proliferation, all metabolically demanding, in the ovex mouse
uterus at these time points (Moggs et al. 2004).
Tissue-specific regulation of outer mitochondrial Tom40 protein expression
Because E2 increased the mt/nuclear DNA ratio at 24 h in mammary gland and uterus, with
more of an increase in uterus versus mammary gland, while 4-OHT increased the mt/nuclear
DNA ratio only in uterus (Fig. 4A), we examined the protein level of one component of the
translocase of the outer mitochondrial membrane (TOM) complex which controls the
transport of nuclear-encoded proteins into mitochondria as a representative outer mt
membrane protein (Hoogenraad and Ryan 2001). Tom40 is the pore-forming unit of the
TOM complex (Hill, et al. 1998). E2 increased Tom40 protein levels in mammary gland and
uterus 72 h after treatment (Fig. 4C, D and Supplementary Fig. 5), a result that correlates
with E2-induced mitochondrial biogenesis at 24 h in these tissues which would then detected
at the protein level later, e.g., 72 h as measured here. 4-OHT increased mitochondrial
biogenesis only in the uterus and not in mammary gland after 24 h and likewise Tom40
protein was increased only in the uterus after 72 h.
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E2 and 4-OHT regulate nuclear-encoded NRF-1 target genes Cox4 and CycS
Cytochrome oxidase subunit IV (Cox4) and cytochrome C (CycS) are nuclear-encoded,
NRF-1 target genes for OXPHOS. We tested the hypothesis that an increase in NRF-1
protein should result in an increase in the expression of its target genes. Cox4 mRNA
expression was increased in mammary gland with E2 treatment at 6 and 24 h whereas uterine
expression was unaffected by E2 and inhibited by 4-OHT at all time points (Fig. 5A and B).
Cox4 protein was increased in mammary gland and uterus 72 h after E2 and 4-OHT
treatment (Fig. 5C, D and Supplementary Fig. 6A). The reason for the discrepancy between
the absence of an effect of 4-OHT on Cox4 transcript expression and the increase in Cox4
protein detected in MG and the inhibition of Cox4 transcript expression but increase in Cox4
protein in uterus at the 72 h time point is unknown. Among the possible explanations are
increased protein stability, and altered mRNA stability.
CycS expression was significantly increased by E2 in mammary gland and decreased by 4-
OHT in the uterus 72 h after treatment (Fig. 5A, B). Cytochrome C protein levels did not
change in mammary gland of mice treated with either E2 or 4-OHT (Fig. 5D and
Supplementary Fig. 6B). However, E2 increased cytochrome c protein in uterus (Fig. 5C and
Supplementary Fig. 6B), a result in contrast to the lack of change in CycS mRNA (Fig. 5B).
Expression of NRF-1 coactivators PGC-1α and PGC-1β in mouse mammary gland and
uterus
PGC1-α and PGC-1β are essential for NRF-1 regulation of gene expression (Scarpulla 2006;
Scarpulla 2008a). Ppargc1b was increased in mammary gland 6 h after E2 and 4-OHT
treatment (Fig. 6A). In uterus, Ppargc1a was reduced 6 h after 4-OHT treatment, and 24 and
72 h after E2 and 4-OHT treatment (Fig. 6B). Ppargc1b expression was reduced in uterus 24
h after 4-OHT treatment and72 h after E2 and 4-OHT treatment (Fig. 6B). In conclusion,
Ppargc1a expression was not regulated by E2 or 4-OHT in mammary gland and decreased
in uterus (Fig. 6A), consistent with reports that: E2 repressed PGC-1α in mouse uterus
(Macari et al. 2010a), GeoProfile GDS1058 showed Pparg1c in uterus of ovex control, but
not E2-treated ovex CD1 mice 4, 8 or 24 h after treatment. Ovariectomy increased PGC-1α
in mouse brain endothelial cells (Kemper et al. 2013). Our data suggest that Ppargc1a and
Ppargc1b are differentially regulated by E2 and 4-OHT in both mammary gland and uterus.
Colocalization of NRF-1 and coactivator PGC-1α in mouse uterus
To address whether NRF-1 and PGC-1α are expressed in the same cell types in mouse
uterus, IHC staining was performed on tissues from ovex mice treated with E2 for 24 or 48 h
(Fig. 7). NRF-1 staining was more prominent in the cytoplasm in vehicle-treated uterine
tissues. However, both stromal and epithelial cells showed enhanced nuclear staining upon
E2 treatment for 24 h but not for 48 h. PGC-1α staining was observed in both cytoplasm and
nucleus of stromal and epithelial cells in vehicle-treated tissues; however, PGC-1α staining
was primarily in the nucleus in 24 h-treated tissues but not in 48 h-treated tissues. Consistent
with Q-RT-PCR results (see Fig. 6B), staining was reduced in uteri treated with E2 for 24 h
and 48 h compared to vehicle. These results indicate that E2 enhances transient nuclear
translocation of NRF-1 and PGC-1α in adult uteri. Our results also indicate that E2 regulates
NRF-1 and PGC-1α in both immature and mature uteri. Most importantly, it was evident
that NRF-1 and PGC-1α were expressed in virtually all cells in stroma and epithelium and
that they colocalized in the nucleus regardless of treatment.
Discussion
The data presented here are the first study of the regulation of endogenous Nrf1 expression,
NRF-1 target gene expression, and mitochondrial biogenesis in normal mouse mammary
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gland or uterus by E2 and 4-OHT. This is because Nrf1 was not included in microarrays
previously used to identify E2 and TAM regulated genes mouse uterus (Fong et al. 2007;
Fong et al. 2010; Moggs et al. 2004) and mammary gland (Deroo et al. 2009). Earlier, we
reported that E2 and 4-OHT increase NRF-1 transcription in breast cancer cells and
HUVECs (Ivanova et al. 2011; Mattingly et al. 2008; Mattingly and Klinge 2012) and that
E2 activates NRF-1 transcriptional activity and mitochondrial biogenesis in human breast
cancer cells (Ivanova et al. 2011; Mattingly et al. 2008). Because NRF-1 is a master
transcriptional regulator of genes regulating mitochondrial function (Scarpulla 2008a), we
proposed a model that nuclear ER upregulation of NRF-1 which, in turn, stimulates the
transcription of nuclear-encoded mitochondrial genes, thus coordinately regulates nuclear-
mitochondrial transcription and function (Ivanova et al. 2011; Klinge 2008; Mattingly et al.
2008). In normal tissue, E2 increased NRF-1 protein in rat brain (Stirone, et al. 2005) and
reduced Nrf1 mRNA expression in mouse brown adipocytes (Rodriguez-Cuenca, et al.
2007).
Regulation of mitochondrial biogenesis has been largely defined by studies in skeletal and
cardiac muscle, liver, and brown fat (Finck and Kelly 2006, 2007; Scarpulla 2008b). This
study demonstrates that E2 and 4-OHT increase Nrf1 mRNA and protein expression in a
time and tissue-specific manner in mammary gland and uterus. Ppargc1a, Ppargc1b, and
NRF-1-regulated nuclear-encoded genes are also regulated by E2 and 4-OHT in a tissue-
specific manner as summarized Fig. 8. Although Nrf1 expression was increased by E2 and 4-
OHT 6 h after treatment in both mammary gland and uterus, NRF-1 protein was higher in
uterus and E2 transiently increased nuclear NRF-1 and PGC-1α staining 4-OHT increased
Nrf1 mRNA but not NRF-1 protein in mammary gland. The discrepancy between Nrf1
mRNA and protein may result from differences in mRNA stability, but will require further
investigation. Our results for E2 regulation show an expected inverse correlation with recent
data showing that ovariectomy decreased NRF-1, Tfam, and Ppargc1b while increasing
Ppargc1a at both mRNA and protein levels in isolated mouse brain endothelial cells
(Kemper et al. 2013).
Interestingly, our study suggests that the mammary gland appears to be more responsive
than uterus to upregulation of NRF-1 target genes Tfam, Tfb1m and Cox4 after E2 or 4-OHT
treatment. Serial analysis of gene expression (SAGE) identified four OXPHOS genes:
Cox6a2, MtCo1, MtCo3, and MtNd3, upregulated in mammary gland 3 h after a single,
subcutaneous injection of E2 (50 ng) in αERKO mice, allowing the authors to conclude that
E2 regulates the expression of Cox6a2 and the mitochondrial-encoded genes mainly through
ERβ (Aboghe, et al. 2009). Importantly, and commensurate with our results that E2 increases
Tfam in mammary gland, all three mitochondrial-encoded genes upregulated by E2 (MtCo1,
MtCo3, and MtNd3(Aboghe et al. 2009)) are regulated by Tfam (Scarpulla 2008b). Based on
the results summarized in Figure 8 and modeled in Figure 9, we suggest that NRF-1
upregulates its target genes selectively in the mammary gland at least in part because of the
expression of Ppargc1b in mammary gland. In contrast, uterine Ppargc1a and Ppargc1b
expression are decreased with E2 and 4-OHT treatment. Our results agree with other reports
showing that E2 repressed Ppargc1a transcription and reduced PGC-1α protein in mouse
uterus (Macari et al. 2010a) and ovariectomy increased PGC-1α and reduced PGC-1β in
mouse brain endothelial cells (Kemper et al. 2013).
To explain the mechanisms involved in regulation of mouse Nrf1 transcription, we
performed ChIP which revealed increased ERα occupation of the ERE in the Nrf1 promoter
in mammary gland and uterus after E2 and 4-OHT treatment. Similar to ERα ChIP-seq
identification of ERα binding sites in a whole genome study of mouse uterus (Hewitt et al.
2012), we also observed ERα bound directly to the ERE-containing region of the Nrf1
promoter in the uterus of the ovex, control-treated mice. At the same time, our results differ
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from the apparent lack of ERα recruitment to the Nrf1 gene in uterus with 1 h of 0.25 μg E2
injection of ovex C57BL/6J mice in this ChIP-seq analysis; however, the treatment time,
route, and dose of E2 are different between our study and that from the Korach lab (Hewitt
et al. 2012). Interestingly, ERα was recruited to the Tfam gene with E2 treatment in mouse
uterus (Hewitt et al. 2012), commensurate with the increase in Tfam mRNA expression with
E2 in mouse uterus seen 72 h after treatment (Fig. 3B). The ERα occupation of AP-1/ ½ERE
site in Nrf1 intron 3 in mammary gland from 4-OHT treated mice is intriguing because it
corresponds to inhibition of NRF-1 expression in our study. Mechanistically, this
observation may be related to the tethering interaction of ERα with AP-1 (Cerillo, et al.
1998; Heldring, et al. 2011; Paech, et al. 1997), but further experiments will be required to
dissect the molecular mechanisms involved. ChIP-seq demonstrated ERα bound to the first
intron of the Wnt4 and Cdkn1 genes in E2-treated mouse uterus and upregulated expression
(Hewitt et al. 2012), establishing the ability of intron-bound ERα to regulate gene
transcription.
Although Tfam, Tfb1m, and Tfb2m are essential for mitochondrial gene transcription and
DNA replication (Scarpulla 2008a), their regulation by E2 and 4-OHT did not completely
match effects of E2 and 4-OHT on mitochondrial biogenesis. E2 increased mitochondrial
biogenesis in the mammary gland and uterus after 24 h, in agreement with increases in Tfam
and Tfb1m only in the mammary gland. Although 4-OHT increased Tfam and Pgpargc1b in
mammary gland, the mitochondrial biogenesis was not increased. In fact, after 72 h
treatment, 4-OHT reduced mammary gland mitochondrial biogenesis, in agreement with
reduced Tfb2m and the return of Tfb1m to basal 24 h after treatment. This may relate to the
fact that Tfam and Tfb1m alone are insufficient to initiate mtDNA replication and Tfb2m
promotes mtDNA replication more efficiently than Tfb1m (Cotney, et al. 2007). It may also
relate to the proapoptotic activity of tamoxifen in mammary gland (Kotoula, et al. 1993).
A summary of our findings is diagramed in Figure 8 and modeled in Figure 9. E2 and 4-
OHT increase in vivo ERα recruitment to the Nrf1 gene and regulate NRF-1 signaling in
time- and tissue-dependent manner in mouse mammary gland and uterus. NRF-1 activated
more of its target genes in mammary gland than in uterus after E2 or 4-OHT treatment,
whereas more genes were downregulated by E2 and 4-OHT in the uterus. These data are
congruent with a report where only 10 genes were regulated by E2 in mouse mammary gland
(Aboghe et al. 2009) whereas in mouse uterus, E2 altered the expression of 3,538 genes
(Moggs et al. 2004). The increase in NRF-1 target gene Tfam in mammary gland and uterus
6 h after E2 and 4-OHT treatment was different from the time-delayed increase in TFAM
expression detected after E2, not 4-OHT, treatment of ERα-expressing MCF-7 breast cancer
cells (Ivanova et al. 2011), reflecting a report that in vivo uterine gene regulation by E2-ERα
is different from MCF-7 cells and may reflect direct recruitment of liganded ERα to the
mouse Tfam promoter (Hewitt et al. 2012). In conclusion, our data demonstrate that E2 and
4-OHT differentially regulate NRF-1 and its downstream gene targets in mammary gland
and uterus with a stronger impact of E2 on stimulating mitochondrial biogenesis in uterus
than mammary gland.
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Refer to Web version on PubMed Central for supplementary material.
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Figure 1. E2 and 4-OHT increase Nrf1 mRNA and NRF-1 protein expression in mouse
mammary gland and uterus
Ovariectomized C57BL/6 mice were given a single sc injection of sesame oil (vehicle
control), 100 ng E2, or 50 μg 4-OHT and were euthanized 6, 24, or 72 h post injection. A
and B. Q-RT-PCR analysis of Nrf1 mRNA level in mammary gland (MG) (A) and uterus
(B). C and D. NRF-1 protein expression was examined relative to β-actin in MG (C) and
uterus (D) after the indicated time of treatment. Values are the mean ± SEM of 5-10 mice/
treatment group in which control was set to 1 for each treatment time within each blot for
comparison. * p < 0.05 versus vehicle control (Student's t test). Representative western blots
are shown in Supplementary Fig. 1.
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Figure 2. E2 and 4-OHT increase ERα recruitment to the Nrf1 promoter in vivo in a tissue-
dependent manner
A, Diagram of the mouse Nrf1 gene promoter showing locations of ERE, AP-1, ½ ERE, and
ERR-binding sites (ERRBS), transcription and protein coding start sites, as indicated. Exons
(E1, E2, E3, and E4) are indicated as grey boxes. The location of the 3 primers used for
ChIP for ERα on Nrf1 are indicated as light grey boxes above the Nrf1 gene. B, Ovex
C57BL/6 mice were treated with vehicle (control), E2, or 4-OHT for 6 h. ChIP with ERα
antibody or with rabbit pre-immune serum (IgG) was performed with the 3 pairs of ChIP
primers (locations shown in A) for the mouse Nrf1 gene promoter. C, Immunoprecipitated
DNA was normalized to input and IgG control and Q-PCR data are expressed relative to IP
for control-treated mammary gland (MG, left) and uterus (right). Values are the mean ±
SEM of 5 mice/treatment group. * p < 0.05 from control for each primer. D and E, ChIP
results are diagrammed for E2-ERα and 4-OHT-ERα recruitment to the Nrf1 promoter in
MG (D) and uterus (E). The bent arrows indicate transcriptional upregulation of Nrf1
mRNA as measured by Q-PCR (see Fig. 1A).
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Figure 3. E2 and 4-OHT selectively regulate the expression of NRF-1 target genes for mtDNA
transcription and replication
A and B, Q-RT-PCR analysis of the mRNA expression of Nrf1-regulated Tfam, Tfb1m, and
Tfb2m expression in mammary gland (MG) (A) and uterus (B) from ovex mice treated with
vehicle control, E2, or 4-OHT for the indicated time. C and D, Tfam protein expression was
examined in mammary gland (MG in panel C) and uterus (D) 72 h after E2 or 4-OHT
treatment. The data shown are the mean ± SEM of 5-10 mice/treatment group. * p < 0.05
versus vehicle control (Student's t-test). Representative western blots are shown in
Supplementary Fig. 3.
Ivanova et al. Page 17
J Mol Endocrinol. Author manuscript; available in PMC 2014 May 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 4. E2 and 4-OHT differently regulate mitochondrial biogenesis in mouse mammary gland
and uterus
A-B, Total DNA was purified from mammary gland (MG) and uterus of ovex mice treated
with vehicle (control), E2, or 4-OHT for 6, 24 and 72 h. The data are the ratio of the
mitochondrial genome encoded gene mt-ND5 normalized to nuclear-encoded gene Ctfr as
determined by qPCR. Values are the mean ± SEM of 6-15 mice/treatment group. * p < 0.05
versus vehicle control (Student's t-test). C-D, Tom40 protein was examined in MG (C) and
uterus (D) after 72 h treatment. The values are the mean ± SEM of 4-7 mice/treatment
groups. *p < 0.05 versus vehicle control (Student's t-test). Representative western blots are
shown in Supplementary Fig.4.
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Figure 5. E2 and 4-OHT differently regulate the level of NRF-1 target genes involved in
mitochondrial respiration
A and B, Q-RT-PCR analysis of the mRNA expression of Nrf1-regulated genes Cox4 and
CycS in mammary gland (MG) (A) and uterus (B) from ovex mice treated with vehicle
(control), E2, or 4-OHT for the indicated time. Values are the mean ± SEM of 10-15 mice/
treatment group. *p < 0.05 versus vehicle control (Student's t-test). C-D, Cox4 (C) and
cytochrome c (D) protein expression was examined in MG and uterus 72 h after the
indicated treatment. Values are the mean ± SEM of 5-12 mice/treatment group. *p < 0.05
versus vehicle control (Student's t-test). Representative Western blots are shown in
Supplementary Fig. 5.
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Figure 6. E2 and 4-OHT increase Ppargc1b expression in mammary gland and reduce Ppargc1a
and Ppargc1b expression in the uterus
Q-RT-PCR analysis of Ppargc1a and Ppargc1b expression in mammary gland (MG) (A)
and uterus (B) from ovex C57BL/6 mice treated with vehicle (control), E2, or 4-OHT for the
indicated time. Values are the mean ± SEM of 5-10 mice/treatment group. *p < 0.05 versus
vehicle control (Student's t-test).
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Figure 7. E2 increases NRF-1 and PGC-1a nuclear colocalization in uterus and decreases
PGC-1a protein levels
Ovex mice were treated with vehicle (veh, EtOH) or 1 μg E2 for 24 or 48 h. Uterine tissue
sections were stained for NRF-1 (green) and PGC-1α (red). Nuclei were stained with
Hoechst 33258 (blue). LE, luminal epithelium; GE, glandular epithelium; S, stroma. White
scale bar is 10 μm.
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Figure 8. Summary of E2 and 4-OHT regulation of Nrf1, Ppargc1a, Ppargc1b, and Nrf1 target
gene expression in mouse mammary gland and uterus
Changes in the expression of the indicated genes (A) and proteins (B) in mammary gland
(MG) and uterus are expressed relative to vehicle control after the indicated treatment time
(6, 24, or 72 h).
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Figure 9. Model of E2-ERα and 4-OHT-ERα regulation of Nrf1 transcription, NRF-1 regulation
of its target genes, PGC-1 coactivator family expression, Tom40, and mitochondrial biogenesis in
mouse mammary gland and uterus
The E2-ERα-stimulated changes are shown in the top two cell models with mammary gland
on the left and uterus on the right. The 4-OHT-ERα-stimulated changes are shown in the
bottom two cell models with mammary gland on the left and uterus on the right. Of course
since we used whole tissue lysates for the experiments in this study, we cannot attribute
gene/protein changes to a specific cell type. The time (h) at which changes in gene or protein
expression were detected is indicated. Bold black arrows indicate the direction (up- or
down-regulation) of the change of gene expression.
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